All In Biotech

Drug Trial Radar · NCT04782271

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

Safety, Tolerability and Pharmacokinetic Profile of Different Doses of SYL1801 Ophthalmic Solution in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Mar 17, 2021

Primary completion

Dec 21, 2021

Study completion Dec 21, 2021

Sponsor

Lead sponsor
Sylentis, S.A.Industry
Sponsor type
Industry
First posted
Mar 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.

Conditions

  • Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers
  • Choroidal Neovascularization

Interventions

  • SYL18001 sodium Low dose q.dDrug

    1 drop in the randomized eye once daily

  • SYL18001 sodium Middle dose q.dDrug

    1 drop in the randomized eye once daily

  • SYL18001 sodium High dose q.dDrug

    1 drop in the randomized eye once daily

  • SYL18001 sodium High dose b.i.dDrug

    1 drop in the randomized eye twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (1 day of treatment).Time frame: 72 hours after last instillation
  2. Ocular tolerability at the site of administration (cornea and conjunctiva) after last instillation of the assigned dose level (7 days of treatment).Time frame: 72 hours after last instillation
  3. Determination of the maximum Plasma Concentration [Cmax]Time frame: - 15 - 30 minutes, 1- 4 and 24 hours after last administration
  4. Determination of the Area Under the Curve of plasma concentrations until the last extraction time [AUT 0-t]Time frame: - 15 - 30 minutes, 1- 4 and 24 hours after last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sylentis Clinical Trial Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.